Moleculin gains after UNC partnership to study new pancreatic cancer treatment

Moleculin Biotech

12/11/2025 15:10

Updates

** Shares of drug developer Moleculin Biotech MBRX.O rise 4.22% to $0.489 premarket

** Company says it has signed an agreement with the University of North Carolina at Chapel Hill to begin preclinical research on new drug annamycin for pancreatic cancer

** Under the deal, Moleculin will provide the experimental drug to UNC researchers led by Professor William C. Zamboni - MBRX

** The team will study how well annamycin reaches pancreatic tumors compared to existing treatments, and whether combining it with other agents can improve results - Company

** The drug is already being tested in late-stage trials for leukemia and soft-tissue cancers and has received U.S. FDA's Fast Track and Orphan Drug status

** MBRX says it is currently running a global late-stage trial of annamycin for leukemia patients who have not responded to other treatments

** Including session's move, stock down ~71% YTD

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))